LAPS-Insulin (HM12460A) / Hanmi - LARVOL DELTA

Preoperative oral carbohydrates in elderly patients undergoing free flap surgery for oral cancer: randomized controlled trial. (PubMed, Int J Oral Maxillofac Surg) - "Thirst (P = 0.001) and hunger (P = 0.003) differed significantly between the two groups prior to anaesthesia induction. The intake of oral carbohydrate 2 hours before surgery was both safe and effective for elderly patients with oral cancer undergoing free flap surgery and could relieve the physiological stress response."

Journal • Anesthesia • Head and Neck Cancer • Oncology • Oral Cancer • Solid Tumor

Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus (clinicaltrials.gov) - P1; N=21; Terminated; Sponsor: Hanmi Pharmaceutical Company Limited; Suspended ➔ Terminated; Sopnsor decision

Clinical • Trial termination • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus (clinicaltrials.gov) - P1; N=21; Suspended; Sponsor: Hanmi Pharmaceutical Company Limited; Trial completion date: Sep 2019 ➔ Sep 2020

Clinical • Trial completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus (clinicaltrials.gov) - P1; N=48; Recruiting; Sponsor: Hanmi Pharmaceutical Company Limited

New P1 trial • Biosimilar • Diabetes • Metabolic Disorders

Molar Potency Study of HM12460A in Healthy Subjects (clinicaltrials.gov) - P1; N=38; Completed; Sponsor: Hanmi Pharmaceutical Company Limited; Recruiting ➔ Completed; Trial primary completion date: Feb 2019 ➔ Feb 2018

Trial completion • Trial primary completion date • Biosimilar

Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus (clinicaltrials.gov) - P1; N=21; Suspended; Sponsor: Hanmi Pharmaceutical Company Limited; Terminated ➔ Suspended

Clinical • Trial suspension

Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus (clinicaltrials.gov) - P1; N=21; Terminated; Sponsor: Hanmi Pharmaceutical Company Limited; N=48 ➔ 21; Recruiting ➔ Terminated; Trial primary completion date: Jun 2019 ➔ Jan 2019; Administrative reasons

Clinical • Enrollment change • Trial primary completion date • Trial termination